Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Free Cash Flow (2019 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Free Cash Flow for 3 consecutive years, with -$24.4 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Free Cash Flow fell 53.17% year-over-year to -$24.4 million, compared with a TTM value of -$102.9 million through Dec 2021, down 96.71%, and an annual FY2024 reading of -$62.3 million, up 6.66% over the prior year.
  • Free Cash Flow was -$24.4 million for Q4 2021 at Black Diamond Therapeutics, up from -$28.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$5.0 million in Q2 2019 and bottomed at -$28.0 million in Q3 2021.
  • Average Free Cash Flow over 3 years is -$15.0 million, with a median of -$12.5 million recorded in 2020.
  • The sharpest move saw Free Cash Flow tumbled 171.45% in 2020, then crashed 53.17% in 2021.
  • Year by year, Free Cash Flow stood at -$7.5 million in 2019, then crashed by 112.55% to -$15.9 million in 2020, then crashed by 53.17% to -$24.4 million in 2021.
  • Business Quant data shows Free Cash Flow for BDTX at -$24.4 million in Q4 2021, -$28.0 million in Q3 2021, and -$25.7 million in Q2 2021.